Export Ready — 

Lipoprotein (a) as a cause of statin-resistance: how to treat? – Case report

Bibliographic Details
Main Author: Négrier Lourenço, Carolina
Publication Date: 2009
Other Authors: Rebelo, Marta, Gaspar, Elsa, Vieira, Diniz, Silva, José Manuel, Alves de Moura, J. J.
Format: Article
Language: por
Source: Repositórios Científicos de Acesso Aberto de Portugal (RCAAP)
Download full: https://revista.spmi.pt/index.php/rpmi/article/view/1380
Summary: Lipoprotein (a) (Lp(a)) is considered to be a cardiovascular risk factor, and nicotinic acid is the only available drug that reduces its levels.The authors present the case of a 44-year-old male patient with hypercholesterolemia that responded poorly to statin therapy. After identifying elevated Lp(a) levels combined therapy with nicotinic acid was initiated, resulting in normalization of LDL-cholesterol levels. The authors also make a theoretical review of Lp(a) and nicotinic acid.
id RCAP_11d29c83b41f29c14de63d43f9714fe1
oai_identifier_str oai:oai.revista.spmi.pt:article/1380
network_acronym_str RCAP
network_name_str Repositórios Científicos de Acesso Aberto de Portugal (RCAAP)
repository_id_str https://opendoar.ac.uk/repository/7160
spelling Lipoprotein (a) as a cause of statin-resistance: how to treat? – Case reportLipoproteína (a) como causa de resistência às estatinas: como tratar? – A propósito de um caso clínicoLipoproteína(a)colesterol LDLrisco cardiovascularácido nicotínicoLipoprotein (a)LDL-cholesterolcardiovascular risknicotinic acidLipoprotein (a) (Lp(a)) is considered to be a cardiovascular risk factor, and nicotinic acid is the only available drug that reduces its levels.The authors present the case of a 44-year-old male patient with hypercholesterolemia that responded poorly to statin therapy. After identifying elevated Lp(a) levels combined therapy with nicotinic acid was initiated, resulting in normalization of LDL-cholesterol levels. The authors also make a theoretical review of Lp(a) and nicotinic acid.A Lipoproteína (a) (Lp(a)) é considerada um factor de risco cardiovascular, sendo o ácido nicotínico o único fármaco disponível para reduzir os seus níveis.Os autores apresentam o caso clínico de um doente do sexo masculino, 44 anos de idade, que apresentava uma hipercolesterolemia de fraca resposta ao tratamento com estatinas. Na sequência da detecção de valores elevados de Lp(a), foi iniciado tratamento combinado com ácido nicotínico, após o qual houve redução dos níveis de colesterol LDL para valores dentro do intervalo indicado nas directrizes internacionais. Os autores fazem também uma revisão teórica sobre Lp(a) e ácido nicotínico.Sociedade Portuguesa de Medicina Interna2009-03-31info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttps://revista.spmi.pt/index.php/rpmi/article/view/1380Internal Medicine; Vol. 16 No. 1 (2009): Janeiro/ Março; 22-26Medicina Interna; Vol. 16 N.º 1 (2009): Janeiro/ Março; 22-262183-99800872-671Xreponame:Repositórios Científicos de Acesso Aberto de Portugal (RCAAP)instname:FCCN, serviços digitais da FCT – Fundação para a Ciência e a Tecnologiainstacron:RCAAPporhttps://revista.spmi.pt/index.php/rpmi/article/view/1380https://revista.spmi.pt/index.php/rpmi/article/view/1380/942Négrier Lourenço, CarolinaRebelo, MartaGaspar, ElsaVieira, DinizSilva, José ManuelAlves de Moura, J. J.info:eu-repo/semantics/openAccess2022-12-31T06:11:30Zoai:oai.revista.spmi.pt:article/1380Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireinfo@rcaap.ptopendoar:https://opendoar.ac.uk/repository/71602025-05-28T10:45:32.354439Repositórios Científicos de Acesso Aberto de Portugal (RCAAP) - FCCN, serviços digitais da FCT – Fundação para a Ciência e a Tecnologiafalse
dc.title.none.fl_str_mv Lipoprotein (a) as a cause of statin-resistance: how to treat? – Case report
Lipoproteína (a) como causa de resistência às estatinas: como tratar? – A propósito de um caso clínico
title Lipoprotein (a) as a cause of statin-resistance: how to treat? – Case report
spellingShingle Lipoprotein (a) as a cause of statin-resistance: how to treat? – Case report
Négrier Lourenço, Carolina
Lipoproteína(a)
colesterol LDL
risco cardiovascular
ácido nicotínico
Lipoprotein (a)
LDL-cholesterol
cardiovascular risk
nicotinic acid
title_short Lipoprotein (a) as a cause of statin-resistance: how to treat? – Case report
title_full Lipoprotein (a) as a cause of statin-resistance: how to treat? – Case report
title_fullStr Lipoprotein (a) as a cause of statin-resistance: how to treat? – Case report
title_full_unstemmed Lipoprotein (a) as a cause of statin-resistance: how to treat? – Case report
title_sort Lipoprotein (a) as a cause of statin-resistance: how to treat? – Case report
author Négrier Lourenço, Carolina
author_facet Négrier Lourenço, Carolina
Rebelo, Marta
Gaspar, Elsa
Vieira, Diniz
Silva, José Manuel
Alves de Moura, J. J.
author_role author
author2 Rebelo, Marta
Gaspar, Elsa
Vieira, Diniz
Silva, José Manuel
Alves de Moura, J. J.
author2_role author
author
author
author
author
dc.contributor.author.fl_str_mv Négrier Lourenço, Carolina
Rebelo, Marta
Gaspar, Elsa
Vieira, Diniz
Silva, José Manuel
Alves de Moura, J. J.
dc.subject.por.fl_str_mv Lipoproteína(a)
colesterol LDL
risco cardiovascular
ácido nicotínico
Lipoprotein (a)
LDL-cholesterol
cardiovascular risk
nicotinic acid
topic Lipoproteína(a)
colesterol LDL
risco cardiovascular
ácido nicotínico
Lipoprotein (a)
LDL-cholesterol
cardiovascular risk
nicotinic acid
description Lipoprotein (a) (Lp(a)) is considered to be a cardiovascular risk factor, and nicotinic acid is the only available drug that reduces its levels.The authors present the case of a 44-year-old male patient with hypercholesterolemia that responded poorly to statin therapy. After identifying elevated Lp(a) levels combined therapy with nicotinic acid was initiated, resulting in normalization of LDL-cholesterol levels. The authors also make a theoretical review of Lp(a) and nicotinic acid.
publishDate 2009
dc.date.none.fl_str_mv 2009-03-31
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv https://revista.spmi.pt/index.php/rpmi/article/view/1380
url https://revista.spmi.pt/index.php/rpmi/article/view/1380
dc.language.iso.fl_str_mv por
language por
dc.relation.none.fl_str_mv https://revista.spmi.pt/index.php/rpmi/article/view/1380
https://revista.spmi.pt/index.php/rpmi/article/view/1380/942
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Sociedade Portuguesa de Medicina Interna
publisher.none.fl_str_mv Sociedade Portuguesa de Medicina Interna
dc.source.none.fl_str_mv Internal Medicine; Vol. 16 No. 1 (2009): Janeiro/ Março; 22-26
Medicina Interna; Vol. 16 N.º 1 (2009): Janeiro/ Março; 22-26
2183-9980
0872-671X
reponame:Repositórios Científicos de Acesso Aberto de Portugal (RCAAP)
instname:FCCN, serviços digitais da FCT – Fundação para a Ciência e a Tecnologia
instacron:RCAAP
instname_str FCCN, serviços digitais da FCT – Fundação para a Ciência e a Tecnologia
instacron_str RCAAP
institution RCAAP
reponame_str Repositórios Científicos de Acesso Aberto de Portugal (RCAAP)
collection Repositórios Científicos de Acesso Aberto de Portugal (RCAAP)
repository.name.fl_str_mv Repositórios Científicos de Acesso Aberto de Portugal (RCAAP) - FCCN, serviços digitais da FCT – Fundação para a Ciência e a Tecnologia
repository.mail.fl_str_mv info@rcaap.pt
_version_ 1833591207397163008

Similar Items